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Rhabdoid tumor is a rare, aggressive, and highly fatal disease that typically presents in the kidneys of
children. Extrarenal rhabdoid tumor has been identiﬁed in various tissue types throughout the body,
most commonly in the brain, but despite its wide phenotypic diversity nearly all rhabdoid tumors share
the same genotypic origin. We present a case of rhabdoid tumor of the brachial plexus, the second such
case to be reported, and a brief review of the literature. Our patient is a ﬁve-year-old female who pre-
sented with sensorimotor symptoms of her arm. Her initial imaging suggested a possible malignant
peripheral nerve sheath tumor. She underwent surgical decompression via an infraclavicular approach;
complete resection was not possible. The pathology was consistent with extrarenal rhabdoid tumor. She
is being treated with alternating cycles of chemotherapy consisting of ICE and VDC.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rhabdoid tumor (RT) was ﬁrst described as a rare variant of
Wilms tumor, accounting for less than 2% of childhood renal tumors
[1]. The median age of diagnosis is 11e18 months [2,3]. It typically
presents as high-stage disease, and progresses rapidly with most
deaths occurring within 12 months of presentation [4]. RT also
occurs outside of the kidney, most commonly in the brain but
throughout the rest of the body as well, where it is even rarer and
deadlier. About 15 cases of extracranial extrarenal rhabdoid tumor
(ERRT) are diagnosed each year in North America [5]. Childrenwith
ERRT present at an older age and a lower stage compared to those
with renal RT [6], and demonstrate a three-year survival rate of only
nine percent [2]. Despite advancements in diagnostic technologies
and a growing body of literature over the past several decades, the
diagnosis of ERRT remains difﬁcult, and the prognosis poor. We
report our experience in the diagnosis and treatment of a child
presenting with a symptomatic rhabdoid tumor of the brachial
plexus.leisa@uci.edu (A. Leis).
rvine School of Medicine,
r Ave, Suite 650, Orange, CA
Inc. This is an open access article u2. Case report
The patient is a ﬁve-year-old, left-hand-dominant female with
no signiﬁcant past medical or family history who presented to the
Children's Hospital of Orange County (CHOC) Emergency Depart-
ment after experiencing four months of left shoulder pain. Her
mother noted a progressive decline in movement of the patient's
left arm and a transition from left-to right-handed writing. X-rays
of the left upper extremity were unremarkable and the patient was
discharged with a diagnosis of pain secondary to an unknown
cause. A subsequentMRI at an outside facility showed a left brachial
plexus mass; she was admitted to the CHOC Oncology service
shortly thereafter. Physical examination revealed mild tenderness
to palpation of the left anterior shoulder superior to the axilla,
moderate weakness consistent with an anterior interosseus nerve
palsy, andmild weakness of the rest of the arm. Her pain andmotor
impairment progressively worsened over the course of her hospi-
talization. MRI with and without contrast showed two heteroge-
neously enhancing fusiform soft tissue masses originating from the
vertebral canal and involving the lateral and posterior cords of the
brachial plexus with non-enhancing central necrosis suggestive of
neuroﬁbrosarcoma or a variation thereof (Fig. 1). The masses were
isointense with adjacent muscle in T1-weighted sequences and
hyperintense in T2.
Nerve conduction studies demonstrated evidence of patchy
subacute brachial plexopathy involving all cords; trunk involve-
ment was not assessed due to the study being limited by patientnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. MRI showing two fusiform, heterogenous soft tissue masses suggestive of a
peripheral nerve sheath tumor. This contrast-enhanced, T2-weighted MRI with Dixon
method fat suppression revealed masses presumed to be arising from the lateral and
posterior cords of the left brachial plexus. The fusiform shape and heterogeneous
enhancement pattern with a central nonenhancing necrosis was suggestive of a
possible malignant neuroﬁbrosarcoma.
Fig. 2. Surgical specimen demonstrating a small-round-blue-cell tumor. This high-
powered view of a section of the tumor stained with hematoxylin and eosin shows
some of the classic “rhabdoid” cytological features: rounded or polygonal cells,
eccentric and vesicular nuclei, and prominent nucleoli, although the typical abundance
of “glassy” eosinophilic cytoplasm is not apparent.
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neuroﬁbromatosis type 1, nor did her clinical presentation or
physical exam.
The patient's mother agreed to surgical exploration for diag-
nostic purposes. After preparation and induction in the operating
suite, signiﬁcantly large palpable masses were identiﬁed in the
axillary and supraclavicular regions that were not appreciable on
preoperative examination due to patient discomfort while awake.
An infraclavicular approach was centered over the most prominent
portion of the palpable mass. Immediately deep to the pectoralis
minor tendon was a large mass that was presumably involving the
lateral cord, although no normal nerve architecture could be
identiﬁed. Upon gentle probing, the mass ruptured, extruding a
thick gelatinous material that was sent for frozen specimen and
culture. A large segment of the tumor was additionally decom-
pressed and sent for permanent specimen. After further decom-
pression, the presumptive posterior cord mass became visible and
was similarly decompressed. The pathologist identiﬁed the frozen
specimen as a small-round-blue-cell tumor (Fig. 2), and thus
reconstruction was deferred and the procedure concluded in light
of the apparent malignancy. The patient's post-operative course
was unremarkable and she was discharged home pending the ﬁnal
pathology report (see Section 2.1 Pathology).
Following her diagnosis of extrarenal rhabdoid tumor, the pa-
tient was readmitted to evaluate for metastatic disease and to
initiate chemotherapy with alternating cycles of ifosfamide, car-
boplatin, etoposide (ICE) and vincristine, doxorubicin, cyclophos-
phamide (VDC) based on tumor board recommendations. There
was no evidence of metastasis on her workup. The interval between
discovery of the mass on imaging and initiation of chemotherapy
was seven weeks. Additional surgical resection was ruled out
because of the tumor's extension into the vertebral canal. Since
beginning chemotherapy, the patient has been hospitalized ﬁve
times for febrile neutropenia or pancytopenia. Functionality of herleft upper extremity has improved but remains impaired. The mass
is smaller on MRI, metabolic activity is reduced on PET, and she
remains free of metastatic disease. However, she remains surgically
unresectable.
2.1. Pathology
Pathologists at CHOC conducted immunohistochemistry studies
on the tumor specimen and found the tumor to stain weakly pos-
itive multifocally for CD99, WT1, FLI1, and synaptophysin, scantly
positive for EMA and S-100, and negatively for myogenin,
myoglobin, Myo-D1, desmin, TLE1, CK7, chromogranin, and NSE.
Fluorescence in situ hybridization (FISH) (Genetics Center, Orange,
CA) was negative for gene rearrangement of CIC (19q13, undiffer-
entiated small round cell sarcoma), SYT/SS18 (18q11.2, synovial
sarcoma) and EWSR1 (22q.12, Ewing sarcoma). Tumor specimens
were then sent to pathologists at Brigham and Women's Hospital
(Boston, MA) and Mayo Clinic (Rochester, MN) for further analysis.
Immunostaining showed weak multifocal membranous positivity
for CD99, multifocal nuclear positivity for WT-1 and scattered
cellular positivity for CAM 5.2 and EMA. Staining was negative for
desmin, LCA, TdT, CCNB3, NUT, CD34, p63, pan-keratin, and INI-1.
Based on the results of the pathologic studies, particularly the
focal positivity for CAM 5.2 and EMA, and the loss of INI-1 indi-
cating deletion of SMARCB1 on 22q11.2, a ﬁnal tissue diagnosis of
extrarenal rhabdoid tumor was made. Eight months later, deletion
of SMARCB1 exons 1e9 in the tumor genome was conﬁrmed by
comprehensive mutation analysis performed by geneticists at The
University of Alabama at Birmingham.
3. Discussion
3.1. Rhabdoid tumor
Rhabdoid tumor was initially described by Beckwith and Palmer
as an aggressive, treatment-resistant, rhabdosarcomatoid variant of
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Study (NWTS 1) [1]. Malignant rhabdoid tumor (MRT) was later
determined to be a distinct clinicopathologic entity in 1981 by Haas
et al. [7] and was deﬁnitively characterized in 1989 byWeeks et al.,
who noted its wide histological diversity incorporating mesen-
chymal, epithelial, and neural phenotypes [2]. MRT is rare, ac-
counting for 1.6% of the childhood renal tumors registered in NWTS
1e5, has no apparent racial predilection and occurs slightly more
frequently in males at a ratio of 1.5:1. Themedian age at diagnosis is
between 11 and 18 months [2,3]. It typically presents as high-stage
disease (III-IV) [2] and progresses rapidly, with most deaths
occurringwithin 12months of presentation [4]. The overall survival
rate for patients with MRT enrolled in NWTS 1e5 was 23.2%.
Rhabdoid tumor (RT) has since been identiﬁed at extrarenal
locations throughout the body, leading to the current nomenclature
which separates rhabdoid tumors into three anatomically-based
categories: malignant rhabdoid tumor (MRT) of the kidney
(sometimes abbreviated RTK), atypical teratoid/rhabdoid tumor
(AT/RT) of the brain, and extrarenal rhabdoid tumor (ERRT) of
extrarenal, extracranial sites (sometimes abbreviated EERT). RT
may also present as congenital disseminated disease [8,9].
Despite their phenotypic diversity, nearly all rhabdoid tumors
have the same genotypic origin: deletion of the SWI/SNF related,
matrix-associated, actin-dependent regulator of chromatin, sub-
family B, member 1 (SMARCB1) gene, also known as human sucrose
nonfermenting gene number 5 (hSNF5), integrase interactor 1
(INI1), and 47-Kd Brg1/Bameassociated factor (BAF47), located at
chromosome locus 22q11 [10]. SMARCB1 encodes a member of the
human SWI/SNF complex and is presumed to function as a classic
tumor suppressor, such that biallelic inactivation of the gene is
considered the genetic basis of rhabdoid tumorigenesis [11]. Loss of
SMARCB1 function and subsequent disruption of the SWI/SNF
complex activates the WNT/b-Catenin pathway and leads to alter-
ations in the epigenetic regulation of the cell cycle, proliferation,
and differentiation at the level of chromatin [12,13]. Belying its
aggressive nature, SMARCB1 alteration appears to be one of a small
number if not the sole mutation in the RT genome, which is
remarkably stable and intact [14]. Germline mutation is present in
around 35% of rhabdoid tumors, is more common in patients with a
family history of RT or with multiple primary tumors [15], is
associated with an earlier onset (median age at diagnosis of 6
months versus 18 months in sporadic cases) [16], and portends a
poorer prognosis [17]. About ﬁve percent of RT have no mutation in
SMARCB1, instead showing alterations to the SMARCA4 gene, the
signiﬁcance of which is still being investigated [18]. Additionally,
SMARCB1 deﬁciency is not 100% speciﬁc for RT as nonrhabdoid
tumors have demonstrated its absence [19].
3.2. ERRT
Rarer than AT/RT of the brain [20], extracranial ERRT have
nonetheless been reported in virtually every part of the body
including the skin, soft tissues, and internal organs [21e24], with a
possible predilection toward the mediastinal and paravertebral
regions [25]. According to the NWTS registry, only about 15 cases of
ERRTare diagnosed each year in North America [5], while data from
the United Kingdom National Registry of Childhood Tumors sug-
gests an incidence of about 0.15 per million among children less
than 15 years old. Children with ERRT present at an older age and a
lower stage compared with those with renal RT [6]. Like its renal
and cranial counterparts, ERRT is a deadly disease, with a three-
year survival rate of only nine percent [2]. In a single-institution
series of nine cases of ERRT spanning a 20-year period, nobody
survived longer than nine months after tumor progression or
recurrence. Patients with localized tumor that could be completelyresected surgically were most likely to survive long-term [26].
3.3. ERRT of the brachial plexus
To the best of our knowledge, this is the second reported case of
rhabdoid tumor involving the brachial plexus of a child, with Rizzo
et al. describing that of a 21-month-old male in the ﬁrst published
series of RT of the peripheral nervous system [27]. Two cases of
brachial plexus RT have been reported in neonates [24], one of
which presented as congenital disseminated disease [8]. In 2009
Strom et al. described a six-year-old female with a primary “axil-
lary” RT, the ﬁrst case of RT of a peripheral nerve according to the
authors [28]. Other cases of axillary tumors did not further specify
the location or the tissue involved [25]. Related cases include those
of cervical [16] and sacral [29] spinal canal involvement, which,
similar to our case, mimicked a malignant peripheral nerve sheath
tumor on imaging.
3.4. Diagnosis and treatment of ERRT
Despite advancements in diagnostic technologies and a growing
body of literature over the past several decades, the diagnosis of
ERRT remains difﬁcult, and the prognosis poor. After it was ﬁrst
described in 1982 [30], purported cases of extrarenal rhabdoid
tumor (ERRT) abounded in the literature, leading many to question
whether these were true cases of ERRT or simply undifferentiated
subtypes of other established sarcomas or carcinomas with rhab-
doid features [31e33]. The two largest series of extrarenal soft-
tissue tumors with rhabdoid features attempting to clarify the di-
agnoses were published by Kodet et al., in 1991, who argued in
favor of a clinical entity distinct from epithelioid and rhabdomyo-
sarcoma [4], and Parham et al., in 1994, who reviewed 42 purported
cases of ERRT and reached the same diagnosis in only 11 of them
(although they preferred the term “poorly differentiated neoplasm
with rhabdoid features”) [34]. With advancements in genetic
analysis came the recognition that the large majority of rhabdoid
tumors, whether renal, extrarenal, or intracranial, have genetic al-
terations to SMARCB1, suggesting that MRT, ERRT, and AT/RT are
closely related if not identical clinicopathologic entities [21,35,36],
distinct from other soft tissue neoplasms [37].
The utility of radiological imaging in establishing the diagnosis
is currently limited. ERRToften shows nonspeciﬁc hypointensity on
T1-weighted magnetic resonance imaging, heterogeneous hyper-
intensity on T2-weighted images, and heterogeneous enhance-
ment, but no radiological ﬁndings are speciﬁc to ERRT [25]. In the
peripheral nervous system RT series by Rizzo et al., zero out of 11
cases were initially suspected to be RT based on radiologic features;
a neuroblastic tumor was suspected in six of them and a peripheral
nerve tumor in four. Furthermore, the ﬁrst histologic diagnosis was
RT in only ﬁve cases. Eight patients had neurological symptoms up
to one year prior to diagnosis, with amean delay before diagnosis of
three months for the cohort [27]. Our patient was diagnosed seven
weeks after the mass was identiﬁed on MRI and about six months
after symptom onset.
Multiple studies using an array of treatment protocols incor-
porating doxorubicin, cyclophosphamide, vincristine, ifosfamide,
carboplatin, and etoposide, as well as high-dose chemotherapy,
have failed to show a superior regimen [23,38e40]. The product of
epigenetic dysregulation alone, rhabdoid tumor is perhaps the
prototypical target of the burgeoning ﬁeld of epigenetic therapy.
Inhibitors of histone modiﬁers believed to be altered by SMARCB1
loss, such as enhancer of zeste 2 polycomb repressor complex 2
(EZH2) and histone deacetylase (HDAC), are in the early stages of
development and have been shown to sensitize rhabdoid tumor
cells to radiation and chemotherapy [16]. MicroRNAs, which are
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ment of multi-drug resistance are another subject of pre-clinical
investigation [40]. Cyclin D1 and cyclin-dependent kinases (CDKs)
are upregulated with loss of SMARCB1 [41], inspiring the research
and development of CDK inhibitors such as ﬂavopiridol [42] and
LEE011 (www.clinicaltrials.gov identiﬁer NCT01747876). The
aurora-A-kinase inhibitor MLN8237 (Alisertib) may also play a role
in rhabdoid tumor treatment [43,44]. Further pre-clinical research
broadening our understanding of the molecular genetics of rhab-
doid tumorigenesis and continued development of novel therapies
are required before substantial progress in patient care can be
achieved.
4. Conclusion
ERRT is one of the rarest and deadliest malignancies of young
people and should be considered in the routine differential diag-
nosis of soft-tissue tumors in all infants and children, including
those with aggressive tumors of the peripheral nervous system.
While surgical evaluation for possible complete resection is a
critical component of any ERRT treatment protocol, deeper
knowledge of rhabdoid tumorigenesis and more effective molecu-
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